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than FACT-F. PQ could be helpful in monitoring cancer patients
from clinical research or practice.
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OBJECTIVES: To evaluate patient-reported impairment in
health states from the EuroQol (EQ-5D) assessment and derive
UK preference-weighted utilities during periods of disease pro-
gression (PROG), toxicity (TOX), and time without symptoms
of progression or toxicity (TWiST), based on a recent phase
3, randomized, outpatient study of ﬁrst-line treatment of
poor-prognosis patients with advanced renal cell carcinoma
(RCC) randomized to temsirolimus, interferon, or interferon+
temsirolimus. METHODS: In the clinical study, the EQ-5D was
assessed at baseline, week 12, and week 32, at each grade 3 or 4
adverse event (AE), at study discontinuation, and at study end.
Assessments were classiﬁed by their timing into 3 distinct
periods: TOX (during grade 3 or 4 AEs or AE-related study
discontinuation), PROG (during progression/relapse), and
TWiST (during neither progression nor toxicity). Published
UK-population preference weights were applied to patient-
reported impairments on the EQ-5D domains—mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression—to derive utility values, consistent with EQ-5D
methodology (euroqol.org). Median utility scores were com-
pared across the periods of TOX, PROG, and TWiST. The pro-
portion of patients reporting at least one EQ-5D domain at the
highest level of severity was compared across the 3 periods, using
the chi-square test. RESULTS: EQ-5D response rates were 87%
(260/300) during PROG, 40% (230/570) during TOX, and 99%
(278/279) during TWiST. Median utility values were 0.585 and
0.587 during TOX and PROG respectively, compared with 0.689
for the TWiST period (p < 0.0001). The proportion of patients
with at least one of the EQ-5D domains at the highest level of
severity was 34.2% (89/260) during PROG, 38.3% (88/230)
during TOX, and 18.7% (52/278) during TWiST (p < 0.0001).
CONCLUSION: Patients with advanced RCC reported similar
impairment of EQ-5D domains during periods of toxicity and
progression, signiﬁcantly greater than in the absence of both;
translating to corresponding differences in UK preference-
weighted utility levels.
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OBJECTIVES: To estimate utility weights associated with CML-
related health states among layperson respondents in three coun-
tries. METHODS: We elicited interviewer-administered time
trade-off utilities with a 10-year time horizon for seven CML-
related health states, from convenience samples of laypersons in
Australia (n = 79), the UK (n = 100), and Canada (n = 103).
Standardized health state descriptions were derived in consulta-
tion with a panel of oncologists. Interviewers underwent training
and used a single script. Mean utilities with 95% conﬁdence
intervals (CI) were calculated for each health state. A generalized
linear model was used to determine whether utilities, adjusted for
age and sex, differed by country. RESULTS: The mean age of the
combined sample was 46 years and 46% of respondents were
men. Mean (95% conﬁdence interval) utilities among Australian
respondents were: 0.85 (0.81–0.89) for chronic responders (CR),
0.68 (0.63–0.72) for chronic non-responders (CNR), 0.71 (0.67–
0.76) for accelerated responders (AR), 0.40 (0.34–0.45) for
accelerated non-responders (ANR), 0.44 (0.38–0.49) for blast
responders (BR), 0.12 (0.09–0.15) for blast non-responders
(BNR), and 0.52 (0.45–0.59) for adverse events (AE). Utilities
from UK respondents were: 0.90 (0.87–0.93; CR), 0.72 (0.67–
0.77; CNR), 0.77 (0.73–0.82; AR), 0.53 (0.48–0.57; ANR), 0.55
(0.51–0.60; BR), 0.29 (0.24–0.34; BNR), and 0.52 (0.46–0.57;
AE). Utilities from Canadian respondents were: 0.72 (0.66–0.77;
CR), 0.56 (0.51–0.62; CNR), 0.58 (0.52–0.63; AR), 0.44 (0.39–
0.49; ANR), 0.38 (0.34–0.43; BR), 0.26 (0.22–0.30; BNR), and
0.34 (0.28–0.39; AE). Signiﬁcant differences were observed
between and among countries. CONCLUSION: These data dem-
onstrate the deteriorating impact on quality of life assigned to
disease states occurring through progression of CML. This is one
of the ﬁrst studies to identify systematic differences between
countries in utility weight estimates for oncological health states.
This observation adds to evidence from other disease areas that
systematic differences exist in utilities between countries.
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OBJECTIVES: To know which attributes related to treatment
administration are valued highly in patients with lung cancer
through the conjoint analysis. METHODS: A literature review
was carried out to identify the attributes related to treat-
ment. There were 6 attributes:1-Time spent in the hospital for
treatment administration. 2-Immediate toxicity. 3-Symptoms’
control. 4-Conﬁdence with the physician. 5-Survival. 6-
Treatment administration. Taking into account these attributes
we elaborated 16 hypothetic scenarios. Through interviews with
2nd line lung cancer patients we asked them to order by preferred
scenario. RESULTS: 24 patients were interviewed, with a mean
(SD) age of 60.8 (11.6) years. 58.3% were men. The mean range
by priority order, that is to say, of priority 1 (maximum prefer-
ence) to priority 16 (minimum preference), we observed that the
chosen scenarios in the ﬁrst place were N (No time spent in the
hospital/No immediate toxicity/Moderate symptom control/
Quite a lot of conﬁdence with the physician/More than 6 months
survival/Oral administration) and H (Spending 2 hours per day
during one week in the hospital/No immediate toxicity/Total
control of symptoms/Total conﬁdence with the physician/Less
than 3 months of survival/Oral administration), whereas the ones
less preferred were M (Spending 2 hours per day during one week
in the hospital/No immediate toxicity/No symptom control/Any
conﬁdence with the physician/From 3–6 month survival/
Intravenous administration) and J (No time spent in the hospital/
High immediate toxicity/No symptom control/Any conﬁdence
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